Data on Ensituximab for treatment of pancreatic and colorectal cancers to be presented at ASCO 2011

Neogenix Oncology announced today that Dr. Luis Diaz of The Johns Hopkins University Hospital will present data from Ensituximab, the company’s novel, therapeutic antibody to treat pancreatic and colorectal cancers. The presentation is scheduled at the American Society of Clinical Oncology (ASCO) 2011 Gastrointestinal Cancers Symposium to be held January 20-22, 2011 at the Moscone Center in San Francisco, CA, USA.

"There is a serious need for new therapies for life-threatening cancers, especially pancreatic cancer where very few treatment options exist. We are pleased to be working with the investigators at these prestigious medical establishments for the therapeutic development of Ensituximab," said Dr. Philip M. Arlen, CEO of Neogenix Oncology.

Poster Presentation Information:

Abstract Title: NPC-1C: A novel, therapeutic antibody to treat pancreas and colorectal cancers.

Poster Session Date/Time: Friday January 21st at 11:45am-1:15pm, and 4:45p-6:00pm.

Permanent Abstract ID: 235

Location: Poster Session B

The full abstract can be accessed through the ASCO GI website gicasym and the Neogenix Oncology website, http://www.neogenix. The complete study presentation poster will also be available on the Neogenix website, following the presentation.

SOURCE Neogenix Oncology

Advertisements
This entry was posted in Uncategorized. Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s